Compare Novavax Inc (NVAX) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs SoundHound AI Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: SoundHound AI Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and SoundHound AI Inc for 23 Days on average.
| NVAX | SOUN | |
|---|---|---|
Market Cap | $1.82B | $2.45B |
Volume | 6,198,505 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $12.75 | $21.40 |
52-Week Low | $6.22 | $5.39 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $1.39B | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
SoundHound AI (SOUN) trades at $5.52, down 1.95% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth ($169M in 2025 to $203M in 2026) but deepens net losses (-$14M to -$137M). Recent developments include expansion in banking and QSR sectors with new product OASYS Edge. Analyst consensus is strongly bullish with a $9.33 price target, though high valuation multiples and negative cash flow from operations pose concerns.
Outlook: Growth trajectory and market expansion offer upside potential, but profitability challenges and integration risks from acquisitions require careful monitoring. The stock presents a high-risk, high-reward opportunity in the competitive AI sector, with current price well below analyst targets suggesting potential appreciation if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
